Canaccord raised the firm’s price target on AngioDynamics (ANGO) to $18 from $17 and keeps a Buy rating on the shares. The firm updated its model following better than expected Q1 results and raised guidance.Canaccord expects the momentum to continue and said its results demonstrate why it remains one of their top picks.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANGO:
- AngioDynamics Reports Strong Q1 2026 Growth
- Berkshire to acquire OxyChem, OpenAI reaches $500B valuation: Morning Buzz
- Morning Movers: Occidental higher after $9.7B sale of OxyChem to Berkshire
- AngioDynamics Reports Strong Q1 2026 Financial Results
- Options Volatility and Implied Earnings Moves Today, October 02, 2025